Navigation Links
China Sky One Medical, Inc. Signs Exclusive Distribution Agreement with Shaanxi Buchang Group for Naftopidil Dispersible Tablets
Date:2/24/2009

HARBIN, China, Feb. 24 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that its wholly owned subsidiary, Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang"), signed an exclusive distribution agreement with Shaanxi Buchang Group ("Buchang") for Naftopidil Dispersible tablets with an expected sales target of 100 million RMB (US $14.6 million) over five years.

Naftopidil Dispersible tablets are used to treat benign enlargement of the prostate in middle aged men. Buchang has a strong national sales network for medicines that treat prostate diseases and Jin Chuang selected Buchang as its exclusive sales agent for Naftopidil Dispersible tablets after careful consideration and review. Jin Chuang will monitor and appraise Buchang's sales performance annually and maintains the right to terminate the distribution agreement if Buchang does not meet its expected sales target. Jin Chuang received SFDA approval to produce and distribute Naftopidil Dispersible tablets in 2005.

"We look forward to a successful collaboration with Buchang on the sale of Naftopidil Dispersible tablets," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "Naftopidil Dispersible tablets have huge market potential and Buchang has a strong sales network for drugs that treat prostate diseases, which makes this a mutually beneficial agreement. As part of our growth strategy, we will continue to seek out favorable collaborative agreements in R&D, production and sales to further grow the business."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the engagement of Shaanxi Buchang Group to be the national exclusive sales agent of Naftopidil Dispersible tablets. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent
2. Dow AgroSciences, China National Rice Research Institute Announce Collaboration on Rice Research
3. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
4. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
5. China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
6. China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
7. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Syngenta Enters Into Research Collaboration With Anhui Academy, China
9. China Sky One Medical, Inc. CFO to Present at Roth Conference
10. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
11. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... --  Boston Biomedical , an industry leader in the ... pathways, today presented data from two clinical studies for ... Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in ... In a Phase Ib/II study of napabucasin – an ... pathways by targeting STAT3 – colorectal cancer (CRC) patients ...
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... announced the formation of its Medical/Clinical Advisory Board. ... industry veterans who enhance the range and depth ... development of its novel prenatal diagnostic tests.  These ... and strategic guidance for the company,s product development ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... delivery of product vigilance software to leading biopharmaceutical and medical device manufacturers and ... is a fully 21 CFR Part 11-compliant email client designed to provide product ...
Breaking Biology Technology:
(Date:1/4/2017)... the thousands of attendees at this year,s International Consumer Electronics Show (CES), ... measurement devices and services, will be featuring its new line of ULTRA ... special CES Exhibit Suite , the new upper arm and wrist ... WellnessConnected product platform.  Continue Reading ... ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
(Date:12/22/2016)... 2016 SuperCom (NASDAQ:   ... the e-Government, Public Safety, HealthCare, and Finance sectors announced today that ... selected to implement and deploy a community-based supportive services program to ... , further expanding its presence in the state. ... This new program, which is ...
Breaking Biology News(10 mins):